Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - Priority Announcement: Ethics

University of Toronto

$163,649.00

SAFER: Study to Articulate a Framework for Ethical Reflection in Post-Market Pharmacovigilance

FY 2013-14

Summary
What are the ethical dimensions to problems arising from post-market regulation of prescription drugs? In particular, what are the issues that pertain to groups that are underrepresented in pre-market clinical trials, for whom evidence of safety and effectiveness is minimal or non-existent? To date there has been little to no systematic ethical analysis of these issues in the Canadian context, and there is very little in the scholarly ethics literature that addresses post-market drug regulation and surveillance. However, numerous drug safety issues have arisen in the recent past that threaten to undermine public trust in government regulatory systems. Health Canada's ongoing shift towards a life-cycle approach to drug regulation provides an opportunity to identify current and future ethical concerns that can inform this evolution of the regulatory and post-market research system in Canada that aims to protect the public from actual and potential harms arising from safety and efficacy issues. This research aims to develop an empirically informed, stakeholder-vetted ethical framework for post-market drug regulation and research in Canada that can improve the legitimacy of processes and outcomes of the regulatory system.
Program
Operating Grant - Priority Announcement: Ethics
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
300097
Name
Thompson Alison K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Humanities, Social Sciences, Law & Ethics in Health
Projecttitle
SAFER: Study to Articulate a Framework for Ethical Reflection in Post-Market Pharmacovigilance
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$163,649
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Ethics
Keyworddelim
Bioethics; Drug Safety And Effectiveness; Empirical Bioethics; Pharmacovigiliance; Prescription Drugs; Public Health Ethics; Qualitative Research; Vaccines
Abstract
What are the ethical dimensions to problems arising from post-market regulation of prescription drugs? In particular, what are the issues that pertain to groups that are underrepresented in pre-market clinical trials, for whom evidence of safety and effectiveness is minimal or non-existent? To date there has been little to no systematic ethical analysis of these issues in the Canadian context, and there is very little in the scholarly ethics literature that addresses post-market drug regulation and surveillance. However, numerous drug safety issues have arisen in the recent past that threaten to undermine public trust in government regulatory systems. Health Canada's ongoing shift towards a life-cycle approach to drug regulation provides an opportunity to identify current and future ethical concerns that can inform this evolution of the regulatory and post-market research system in Canada that aims to protect the public from actual and potential harms arising from safety and efficacy issues. This research aims to develop an empirically informed, stakeholder-vetted ethical framework for post-market drug regulation and research in Canada that can improve the legitimacy of processes and outcomes of the regulatory system.
Competitiondate
201309
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Thompson, Alison K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $163,649~ $0~
University of Toronto - $163,649 Grant (2013-14) | Canada Spends